Immunology & allergy
Immune system & allergy clinical trials
Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We’re tracking 6,067 recruiting studies in this area right now.
By phase
- Not applicable3,005
- Phase 21,060
- Phase 1794
- Phase 1/Phase 2441
- Phase 3435
- Phase 4233
- Phase 2/Phase 399
Top conditions
- Multiple Sclerosis330
- Multiple Myeloma328
- Asthma194
- Lymphoma179
- Type 1 Diabetes132
- Rheumatoid Arthritis131
- Atopic Dermatitis122
- Systemic Lupus Erythematosus121
- Acute Lymphoblastic Leukemia118
- HIV Infections105
- Chronic Lymphocytic Leukemia96
- Autoimmune Diseases79
- Follicular Lymphoma70
- Rheumatoid Arthritis (RA)68
- Hodgkin Lymphoma64
- Diabetes Mellitus, Type 163
- Leukemia63
- Type 1 Diabetes Mellitus63
Leading sponsors
- National Institute of Allergy and Infectious Diseases (NIAID)97
- Institute of Hematology & Blood Diseases Hospital, China85
- National Cancer Institute (NCI)74
- Assistance Publique - Hôpitaux de Paris65
- AstraZeneca64
- M.D. Anderson Cancer Center58
- Novartis Pharmaceuticals58
- Mayo Clinic50
- City of Hope Medical Center49
- Memorial Sloan Kettering Cancer Center44
Where studies are running
- California498
- Maryland198
- Alabama178
- Florida151
- Arizona150
- Massachusetts118
- New York114
- Texas112
- Illinois84
- Colorado81
Recruiting studies6,067 total
- NCT05663502Recruiting
Donate blood and tissue samples for HIV-related cancer research
This study collects blood and tissue samples to help researchers learn more about cancers related to HIV/AIDS. You may be able to join if you’re 18+ and have HIV and a cancer diagnosis, or (if HIV-negative) a certain cancer that is closely linked to AIDS-related cancers.
La Jolla, CaliforniaAges 18 years+ - NCT05652335RecruitingPhase 1
JNJ-79635322 for hard-to-treat myeloma or amyloidosis
This Phase 1 study tests how safe and how well JNJ-79635322 works in people with multiple myeloma that has come back or is resistant to treatment, or AL amyloidosis that has already been treated. It may help by targeting cancer cells and abnormal proteins driving these diseases.
Duarte, CaliforniaAges 18 years+ - NCT05668403RecruitingPhase 1
Subcutaneous anti-CD20 antibody for primary membranous nephropathy
This Phase 1 study tests a skin-under-the-bone (subcutaneous) antibody medicine that targets CD20 on certain immune cells. It aims to see safety and how the drug may work in people with primary membranous nephropathy, a kidney disease that can cause high urine protein.
Zhengzhou, He'nanAges 18–75 - NCT05640102Recruiting
Study of zanubrutinib in Waldenström macroglobulinemia
This is an observational study that follows people with Waldenström macroglobulinemia (WM) to learn how well zanubrutinib works and how safe it is. Your results will be tracked in relation to your disease features, including a blood/marrow marker called MYD88.
Huntsville, AlabamaAges 18 years+ - NCT05654922RecruitingPhase 3
Prevent lung transplant airways scarring with ARINA-1
This Phase 3 trial tests ARINA-1 to slow or prevent worsening lung transplant scarring in the breathing tubes (bronchiolitis obliterans). It may help people who are showing early decline in lung function but are not yet at advanced disease.
Phoenix, ArizonaAges 18–75 - NCT05669989Enrolling by invitationPhase 2
Continuing isatuximab treatment for multiple myeloma
This study allows people with multiple myeloma who are already benefiting from the drug isatuximab in an earlier clinical trial to keep receiving it after that trial ends. It is an extension study, meaning you can continue your treatment without interruption.
St Louis, MissouriAges 18 years+ - NCT05650632RecruitingPhase 1
IV infusion safety study of etentamig for multiple myeloma
This is an early (Phase 1) study focused on safety of an IV medicine called etentamig in adults with relapsed or refractory multiple myeloma. It looks at how the treatment affects side effects and helps decide the safest way to give it.
Phoenix, ArizonaAges 18 years+ - NCT05658497Recruiting
MS pregnancy registry for Vumerity (diroximel fumarate) exposure
This study collects information about pregnancies in people with multiple sclerosis (MS) who were exposed to Vumerity (diroximel fumarate) or who were not on MS medicines during pregnancy. It helps researchers understand pregnancy outcomes and safety in these situations.
Aurora, ColoradoAges Any age - NCT05645107RecruitingPhase 3
XEMBIFY plus usual care to prevent infections
This Phase 3 study tests whether XEMBIFY (an immune protein therapy) plus standard medical treatment can better prevent serious or repeated infections. It is for people with certain cancers of blood/immune systems who are already having trouble with infections.
Bullhead City, ArizonaAges 18 years+ - NCT05673551Enrolling by invitation
VR during at-home burn dressing changes for kids
This trial tests whether virtual reality (VR) can help children feel better during daily burn dressing changes at home. It will study comfort and pain around the first time you do dressings after leaving the hospital.
Columbus, OhioAges 6–17 - NCT05641753RecruitingPhase 4
LDL-lowering study for adults with type 1 diabetes
This study looks at cholesterol lowering in adults with type 1 diabetes and whether it reduces “residual risk,” meaning risk that may remain even with current care. You may be asked to take cholesterol-focused treatment and complete blood tests to track LDL (“bad cholesterol”).
New York, New YorkAges 18–89 - NCT05642715Recruiting
HIV smoking reduction program with varenicline and online support
This study tests a harm-reduction approach to help people with HIV smoke fewer cigarettes and quit if they want, using an online tobacco program and varenicline (a quit-smoking medicine). You may be placed in one of two different study groups to compare how well the approaches work.
The Bronx, New YorkAges 40–79 - NCT05646394Recruiting
Registry for blood-clot prevention plans in arterial antiphospholipid syndrome
This study keeps a registry to follow people with antiphospholipid syndrome (APS) who have had arterial blood clots (like stroke). It collects information about the treatment approach your clinician chooses to see how different antithrombotic regimens may perform and be tolerated.
Buenos Aires, Buenos Aires F.D.Ages 18 years+ - NCT05672251RecruitingPhase 2
Testing two antibody drugs for lymphoma that came back
This Phase 2 trial tests two targeted antibody medicines—loncastuximab tesirine and mosunetuzumab—in people whose diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma grade 3B has come back or did not respond. It aims to shrink lymphoma that has measurable disease and has specific markers (CD19 and CD20) on tumor cells.
Duarte, CaliforniaAges 18 years+ - NCT05660148Recruiting
HIV study on resentment, forgiveness, and quality of life
This study looks at how feelings like resentment and the ability to forgive relate to quality of life in people living with HIV. You may be asked to participate in questionnaires and/or follow-up that can be done by phone or video.
AmiensAges 18 years+ - NCT05669534RecruitingPhase 4
HIV prevention support for people starting PrEP
This study tests how to better support HIV prevention for people who inject drugs and are newly starting PrEP (medicine to prevent HIV). It focuses on people taking medication for opioid use disorder and who have mild thinking and memory problems, to help them stay safe and adhere to prevention.
New Haven, ConnecticutAges 18 years+ - NCT05642884Recruiting
Pre-surgery program for older adults getting stem cell transplant
This study checks whether a “pre-surgery” health coaching program is practical and safe for older people with multiple myeloma who are scheduled for an autologous stem cell transplant. It may help patients prepare better for transplant recovery, and the study will see if the plan can be carried out smoothly.
Birmingham, AlabamaAges 60 years+ - NCT05657652Recruiting
Medicine regimen for relapsed or refractory B-ALL
This trial studies a specific treatment plan (“CAV regimen”) for people with B-cell ALL that has either come back or did not respond to standard treatment. It may help control the leukemia, if you meet the health and safety requirements.
Suzhou, JiangsuAges 15–70 - NCT05646576Recruiting
Palliative care support during blood cancer cell therapy
This trial studies whether adding palliative care (comfort-focused care to reduce stress and symptoms) helps people during adoptive cell therapy for blood cancers. It may help improve quality of life while you’re receiving the therapy.
Boston, MassachusettsAges 18 years+ - NCT05663216Recruiting
Study of fluid leaks in serious whole-body inflammation
This trial looks at what causes blood vessels to “leak” fluid during a dangerous whole-body inflammation response. It may help doctors understand why some people develop fluid buildup and aim for better monitoring and care in the ICU.
ParisAges 18 years+ - NCT05645510Recruiting
Study for people on long-term cancer targeted medicines
This study looks at people who are already taking long-term targeted cancer medicines. It may help researchers understand how these treatments work over time and whether there are ways to improve care.
Edmonton, AlbertaAges 18–90 - NCT05656105RecruitingEarly Phase 1
PET scan study of brain inflammation after COVID
This early-phase study uses a special PET scan to look for signs of brain inflammation in people with ongoing (long-term) nervous system symptoms after COVID-19. It may help researchers understand what is driving symptoms and whether this imaging approach can detect inflammation.
Birmingham, AlabamaAges 18–65 - NCT05664035Recruiting
Measuring infection patterns in adults with frequent respiratory infections
This study looks at how often “SPAD” happens in adults who get repeated bacterial infections in the chest or sinuses. It aims to better understand your infection frequency and related immune test results, which may help guide future care.
LilleAges 18–65 - NCT05640843Recruiting
Plant-based diet study for MGUS or smoldering myeloma
This trial tests whether a whole-food, plant-based eating pattern—plus supplements or placebo—can improve health outcomes in people with MGUS or smoldering multiple myeloma. You may be asked to follow specific recipes and stop certain supplements, so it helps to confirm you can stick with the plan.
Atlanta, GeorgiaAges 18 years+
Common questions
- How many immune system & allergy clinical trials are recruiting?
- Clin2 is tracking 6,067 recruiting immunology & allergy studies from the U.S. registry right now, out of 9,241 we cover in this area in total.
- What does “Immune system & allergy” cover here?
- Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We group each study into immune system & allergy based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a immune system & allergy trial near me?
- Use the search to filter immune system & allergy studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.